# Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents

> **NCT03445468** · PHASE3 · COMPLETED · sponsor: **Il-Yang Pharm. Co., Ltd.** · enrollment: 379 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** IL-YANG Quadrivalent Influenza Vaccine
- **BIOLOGICAL:** IL-YANG Flu Vaccine Pre-filled Syringe

## Key facts

- **NCT ID:** NCT03445468
- **Lead sponsor:** Il-Yang Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2017-12-29
- **Final completion:** 2018-08-30
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2020-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445468, "Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03445468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*